GeoVax Labs, Inc. announced that Chairman and CEO David Dodd will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Yale Club in New York City. This invitation-only event connects healthcare companies with institutional investors through one-on-one meetings and panel discussions, offering executives the opportunity to discuss corporate strategy and pipeline developments with potential investors.
The conference format includes 25-minute management-investor meetings designed to provide institutional clients with comprehensive insights into participating companies' strategic direction, product pipelines, and upcoming milestones. Dodd will be available throughout the day to discuss GeoVax's clinical-stage programs, including three key therapeutic candidates that represent significant advancements in infectious disease prevention and cancer treatment.
GeoVax's pipeline includes GEO-MVA, an MVA-based vaccine targeting Mpox and smallpox that recently received favorable Scientific Advice from the European Medicines Agency. This regulatory guidance suggests the vaccine candidate may progress directly to Phase 3 clinical evaluation, potentially accelerating its path to market and addressing global preparedness needs for orthopoxvirus threats. The company's position in this space is particularly important given the resurgence of Mpox cases globally and ongoing concerns about smallpox preparedness.
The company's COVID-19 vaccine candidate, GEO-CM04S1, represents another critical development in the ongoing battle against coronavirus variants. Currently being evaluated in three Phase 2 clinical trials, this multi-antigen vaccine is being studied across diverse patient populations, including immunocompromised individuals who often respond poorly to current authorized vaccines. This research addresses a significant unmet medical need, as hematologic cancer patients and other immunocompromised populations remain vulnerable to severe COVID-19 outcomes despite available vaccination options.
In oncology, GeoVax is advancing Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors, with a planned Phase 2 trial focusing on head and neck cancer. This innovative approach represents a novel mechanism for treating challenging solid tumors and could provide new options for patients with limited treatment alternatives. The company's progress in this area demonstrates the expanding potential of biotechnological approaches to cancer treatment beyond traditional chemotherapy and radiation.
For more information about the company's clinical trials and development programs, investors can visit https://www.geovax.com. The original announcement was published on https://www.newmediawire.com.
This conference participation comes at a crucial time for GeoVax as the company advances multiple clinical programs simultaneously. The ability to present these developments to institutional investors provides validation of the company's scientific approach and could facilitate the capital formation necessary to advance these promising therapies through later-stage clinical trials. For the healthcare investment community, GeoVax represents an opportunity to engage with a company addressing multiple significant public health challenges through innovative vaccine and immunotherapy platforms.
The broader implications of GeoVax's work extend beyond investor returns to public health preparedness and patient care. The company's focus on developing vaccines for immunocompromised populations addresses a critical gap in current infectious disease prevention strategies. Similarly, their work on Mpox/smallpox vaccines contributes to global biodefense capabilities at a time when emerging infectious diseases pose increasing threats to public health systems worldwide.
